|
Characteristics of patients with hematologic malignancies without seroconversion post-COVID19 third vaccine dosing (3V): Real-world data from large midwestern healthcare system. |
|
|
Leadership - Association of Community Cancer Centers (ACCC) |
Honoraria - Cardinal Health |
Consulting or Advisory Role - Array BioPharma; Bristol Myers Squibb; Cardinal Health |
Speakers' Bureau - Bristol Myers Squibb |
Travel, Accommodations, Expenses - Bristol Mers Squibb; cardinal health |
(OPTIONAL) Uncompensated Relationships - Society for Immunotherapy of Cancer |
|
|
Employment - Aurora Health Care; Tempus |
Stock and Other Ownership Interests - Doximity; Tempus |
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Celgene; Epizyme; GlaxoSmithKline; GRAIL; Janssen Oncology; Sanofi; Syapse; Takeda; VIA Oncology |
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); Bristol-Myers Squibb (Inst); Cancer Research and Biostatistics (Inst); Denovo Biopharma (Inst); GlaxoSmithKline (Inst); Lynx Biosciences (Inst); PrECOG (Inst); Strata Oncology (Inst); Takeda (Inst); TG Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - UpToDate, Peer Review for Plasma Cell Dyscrasias (Editor: Robert Kyle) |
Travel, Accommodations, Expenses - GlaxoSmithKline; Syapse; Takeda |
Other Relationship - Doximity |
(OPTIONAL) Uncompensated Relationships - Strata Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Kite, a Gilead company |
Consulting or Advisory Role - Kite, a Gilead company |
Speakers' Bureau - Kite, a Gilead company; Kite, a Gilead company |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Via Oncology |
Other Relationship - Elsevier |